The heat is on: Molecular mechanisms of drug-induced hyperthermia

Christine K Dao¹, Sara M Nowinski², and Edward M Mills¹,*

¹Division of Pharmacology and Toxicology; College of Pharmacy; The University of Texas at Austin; Austin, TX USA; ²Department of Biochemistry; University of Utah School of Medicine; Salt Lake City, UT USA

Keywords: non-shivering thermogenesis, uncoupling proteins, hyperthermia, 3,4-methylenedioxymphetamine (MDMA, Ecstasy), UCP3

Abbreviations: α₁AR, α₁-adrenoceptor; β₃AR, β₃-adrenoceptor; BAT, brown adipose tissue; Ca²⁺, calcium ion; FADH₂, flavin adenine dinucleotide; MAOIs, monoamine oxidase inhibitors; LSD, lysergic acid diethylamide; MDMA, ecstasy, methylenedioxymphetamine; NADH, nicotinamide adenine dinucleotide; NST, non-shivering thermogenesis; NE, norepinephrine; RYR1, ryanodine receptor; SSRIs, selective serotonin reuptake inhibitors; SERCA, sarcoplasmic/endoplasmic reticulum-ATPase pump; SKM, skeletal muscle; SNS, sympathetic nervous system; UCP1, uncoupling protein 1; UCP3, uncoupling protein 3; TCA, tricyclic antidepressant.

Thermoregulation is an essential homeostatic process in which critical mechanisms of heat production and dissipation are controlled centrally in large part by the hypothalamus and peripherally by activation of the sympathetic nervous system. Drugs that disrupt the components of this highly orchestrated multi-organ process can lead to life-threatening hyperthermia. In most cases, hyperthermic agents raise body temperature by increasing the central and peripheral release of thermoregulatory neurotransmitters that ultimately lead to heat production in thermogenic effector organs skeletal muscle (SKM) and brown adipose tissue (BAT). In many cases hyperthermic drugs also decrease heat dissipation through peripheral changes in blood flow. Drug-induced heat production is driven by the stimulation of mechanisms that normally regulate the adaptive thermogenic responses including both shivering and non-shivering thermogenesis (NST) mechanisms. Modulation of the mitochondrial electrochemical proton/pH gradient by uncoupling protein 1 (UCP1) in BAT is the most well characterized mechanism of NST in response to cold, and may contribute to thermogenesis induced by sympathomimetic agents, but this is far from established. However, the UCP1 homologue, UCP3, and the ryanodine receptor (RYR1) are established mediators of toxicant-induced hyperthermia in SKM. Defining the molecular mechanisms that orchestrate drug-induced hyperthermia will be essential in developing treatment modalities for thermogenic illnesses. This review will briefly summarize mechanisms of thermoregulation and provide a survey of pharmacologic agents that can lead to hyperthermia. We will also provide an overview of the established and candidate molecular mechanisms that regulate the actual thermogenic processes in heat effector organs BAT and SKM.

**Introduction to Toxicant-Induced Hyperthermia**

The 2 broad categories of medical conditions that result in increased body temperature are hyperthermia and fever. Hyperthermia refers to a catastrophic rise in body temperature resulting from an imbalance between the accumulation of body heat (either from environmental temperature extremes and/or body heat generation) and the capacity to dissipate heat. Hyperthermia typically involves a failure of central hypothalamic autoregulatory body temperature control. In contrast, fever is a regulated process and presents as an adaptive, physiologic response to infection involving a rise in the hypothalamic body temperature “set point.” Although fever can be treated with non-steroidal anti-inflammatory agents (e.g. aspirin, acetaminophen), these drugs are ineffective in the therapeutic use for hyperthermia.¹

A variety of pharmacologic and toxicologic agents can trigger hyperthermia, and in most cases, they do so in large part by altering hypothalamic and sympathetic nervous system (SNS) regulation of body temperature. As depicted in Table 1, the most well characterized drug-induced hyperthermic syndromes include neuroleptic malignant syndrome, serotonin syndrome, sympathomimetic syndrome, and malignant hyperthermia. Hyperthermia typically coincides with devastating medical complications, including hyperkalemia, renal failure, metabolic acidosis, liver...
failure, intravascular coagulation, rhabdomyolysis and death.2,3

Thus, it is essential to understand the molecular changes that are involved in order to effectively treat hyperthermic crises.4 In most cases, the precise mechanisms of drug-induced heat generation are either unknown or only beginning to be understood. Treatment options that target thermogenic responses are currently limited to only small fraction of drug-induced hyperthermic illnesses, and our existing approaches for the vast majority of cases focus mainly on providing supportive care, which involves, external cooling, anxiolytic drugs, and rehydration.2,3,5

Mechanisms of Thermoregulation: The Thermogenic Effector Systems in BAT and SKM

At thermoneutrality, the temperature at which animals need not make “extra” body heat to conserve normal body temperature (~37°C), basal temperature is maintained by the combined inefficiency of all exergonic cellular reactions.6 This is commonly referred to as obligatory thermogenesis. By contrast, in response to chronic cold exposure, feeding, and infection, endotherms can also rapidly increase thermogenesis to defend core body temperature or raise it through physiological heat-generating processes collectively referred to as facultative thermogenesis (see Table 2). The hypothalamus is the predominant, master controller of obligatory and facultative thermogenesis and also coordinates cooling mechanisms that dissipate heat, including sweating (in humans) and cutaneous vasodilation.7,9 A considerable body of work has defined many of the efferent and afferent neuroanatomical networks that signal within, to and from the hypothalamus, spinal cord, and periphery to control thermogenesis and heat dissipation. Although, the central and peripheral regulators of the neurochemical mechanisms that coordinate body temperature and thermogenesis are not the main focus of this manuscript, these pathways have been well-reviewed elsewhere.10,11

When considering the direct thermogenic effector mechanisms of body heat production, only a dramatic increase in cellular “work” (e.g., muscle contraction) or other exergonic biochemical reactions in organs of sufficient metabolic capacity (e.g., BAT, SKM) can increase body temperature. Rapid muscle contraction / shivering is a highly thermogenic mode of SKM facultative thermogenesis that mediates an early and temporary component of the adaptive response to cold and infection. However, shivering is energetically costly and impractical to sustain for extended periods of time. Therefore, endotherms have evolved alternative mechanisms of heat generation that are recruited to withstand prolonged periods of cold exposure without shivering, i.e. non-shivering thermogenesis (NST).12

The 2 predominant thermogenic organs are BAT and SKM. SNS stimulation of BAT mitochondrial uncoupling protein 1 (UCP1) is the prototypical mechanism of NST. The role of UCP1 (originally identified as thermogenin) in heat production was initially characterized in the 1980s.13 UCP1 is part of a highly conserved family of mitochondrial solute carriers that have the ability to dramatically increase mitochondrial respiration and uncouple oxidative phosphorylation from ATP production by dissipating the proton gradient.14 By allowing protons to leak across the mitochondrial inner membrane and circumvent the F1/Fo-ATPase complex of the electron transport chain, UCP1 releases the energy stored in the electrochemical gradient in the form of heat. Mitochondrial proton leak sets up what is commonly referred to as a biochemical futile cycle where 2 metabolic pathways (proton extrusion and proton leak) run simultaneously in opposite directions. The thermogenic futile cycle induced by mitochondrial proton leak is simulated by the metabolic toxicant dinitrophenol, a weak acid that works by localizing to the mitochondrial inner membrane and inducing dose-dependent proton leak. Persons exposed to the drug, either unintentionally in munitions factories or during its brief stint as...
an anti-obesity medicine routinely developed hyperthermia and many died.\textsuperscript{15,16} Sarcoplasmic reticulum calcium extrusion and ATP dependent calcium uptake in SKM is another futile cycle that is implicated in adaptive NST as well as drug-induced hyperthermia (discussed below). Other examples of futile cycles that may be involved in thermoregulation include the simultaneous occurrence of protein synthesis and breakdown (especially in muscle), and leakage of the sodium-potassium ATPase pump.\textsuperscript{17} However, in general, UCP1-dependent mitochondrial proton leak is the most well characterized physiological mechanism of NST in mammals. The extent to which other futile cycles contribute to whole body thermogenesis is unclear.

In the canonical response to cold, the hypothalamus activates the SNS, triggering the release of norepinephrine (NE) from sympathetic neurons that densely innervate BAT tissue depots.\textsuperscript{18} NE binds to $\beta_3$-adrenoreceptors ($\beta_3$AR) on brown adipocytes, initiating a signaling cascade that leads to the generation of free fatty acids from cytoplasmic multilocular lipid droplets via the cyclic AMP-protein kinase A-hormone sensitive lipase signaling pathway.\textsuperscript{19,20} Free fatty acids are then transported into BAT mitochondria via the carnitine shuttle system, where they are used as substrates for $\beta$-oxidation, and activate UCP1-mediated thermogenesis.\textsuperscript{20,21} Studies in genetic mutant mouse models with defects in fatty acid transport and metabolism that exhibit cold-sensitivity phenotypes\textsuperscript{22} reinforce the physiological importance of fatty acids in thermogenesis. On a side note, NE can also interact with $\alpha_1$-adrenoreceptors ($\alpha_1$AR) to stimulate vessel constriction and therefore block heat dissipation.\textsuperscript{23} Support for the classic pathway of $\beta_3$AR-stimulated thermogenesis has been demonstrated in studies where lipolysis and BAT thermogenesis are blocked by administration of the PKA inhibitor, H-89,\textsuperscript{24} and by adrenergic blocking agents.\textsuperscript{25} Likewise, experiments in brown adipocytes show that treatment with fatty acids alone can simulate NE-induced thermogenesis, but only in the presence of UCP1.\textsuperscript{26} Recent elegant studies using mitochondrial patch clamping demonstrated that UCP1 requires long chain fatty acids to associate with and activate UCP1-driven thermogenic proton leak.\textsuperscript{27} Thus, it is the presence and activation of UCP1 by fatty acids in brown adipocytes that endows these cells the specialized ability to generate heat. Although it is unclear the extent to which UCP1 participates in toxicant- and drug-induced hyperthermia, unpublished work in our laboratory shows that UCP1-null mice harbor dramatically blunted thermogenic responses to methamphetamine. These findings are consistent with recent studies demonstrating that mice with surgically ablated or denervated BAT exhibited lower peak temperatures and shorter durations of MDMA-induced hyperthermia.\textsuperscript{28} Together, these findings validate the contribution of sympathetic regulation of BAT-UCP1 thermogenesis in drug-induced hyperthermia.

UCP1 is thought to be primarily, if not exclusively, expressed in BAT. Compared to rodents and newborns, only a fraction of adult humans have significant amounts of BAT.\textsuperscript{29,30} However, BAT tissue is not only activated by SNS stimulation, it can also increase in size in response to SNS activation.\textsuperscript{31-33} Nonetheless, it remains uncertain the extent to which BAT contributes to NST in adults.\textsuperscript{34} It is likely that alternative thermogenic systems in addition to BAT have evolved for the regulation of NST. This notion is supported by studies in animals that completely lack BAT (amphibians, reptiles, and birds) yet still exhibit SNS-dependent thermogenic responses.\textsuperscript{35-37} Furthermore, mice lacking UCP1 still exhibit some, albeit blunted NE-induced thermogenesis.\textsuperscript{38}

Skeletal muscle (SKM) is an attractive site of NST because it is the largest and most highly metabolic organ in the body. However, the mechanisms involved in muscle NST are far less well characterized compared to BAT. Several studies have implied that thermogenic systems similar to the UCP1-regulated pathways may also exist in SKM.\textsuperscript{39-41} The idea that these SKM specific systems are regulated similarly to BAT thermogenesis through adrenergic stimulation is demonstrated in studies showing that NE administration in isolated muscle increases metabolism/thermogenesis.\textsuperscript{42} Interestingly, most if not all types of drug-induced hyperthermic conditions are associated with SKM damage.\textsuperscript{43} For example, malignant hyperthermia (MH) involves a well-defined pharmacogenetic mechanism of drug-induced hyperthermia that arises from muscle in individuals harboring mutations in the SKM ryanodine receptor calcium channel (RYR1). In these patients, in response to volatile anesthetic administration, a highly exergonic futile cycle is created by the excessive release of Ca\textsuperscript{2+} in to the cytoplasm, thus uncoupling the sarcoplasmic / endoplasmic reticulum-ATPase pump (SERCA) from ATP hydrolysis.\textsuperscript{44} Although it is not established whether RYR1 is a direct regulator of NST under normal, physiological circumstances, it is very likely that intramyocyte calcium handling, in general, plays an important role in normal thermoregulation. This idea is corroborated by recent studies showing that mice lacking sarcolinip, a negative regulator of SERCA were unable to defend core body temperature in cold environments.\textsuperscript{41}

The skeletal muscle-enriched UCP1 homolog, UCP3, has also been implicated in drug-induced hyperthermia\textsuperscript{45} and physiological NST responses to thyroid hormone.\textsuperscript{46,47} UCP3, shares more than 50% amino acid homology with UCP1 and has been shown to regulate proton flux in reconstituted systems \textit{in vitro}.\textsuperscript{48,49} Compared to UCP1, UCP3 is more broadly expressed in heart, skeletal muscle, BAT,\textsuperscript{50} and as we recently demonstrated, skin.\textsuperscript{51} UCP3 knock-out SKM mitochondria also show decreased proton leak (i.e., increased “coupling”) in some studies\textsuperscript{52,53} and transgenic mice that overexpress UCP3 exhibit enhanced SKM thermogenesis.\textsuperscript{54} Furthermore, UCP1-null mice exhibit skeletal muscle-specific, cold-induced adaptive thermogenesis that correlates with increased expression of UCP3.\textsuperscript{55} In addition, thyroid hormone, arguably the most important positive endocrine regulator of the majority of obligatory and facultative thermogenic processes, also modulates SKM metabolic efficiency and proton leak.\textsuperscript{46,56} Interestingly, thyrotoxicosis, a dangerous feature of hyperthyroid conditions, is often accompanied by hyperthermia and rhabdomyolysis, but is associated with decreased activity of BAT UCP1.\textsuperscript{57} Thus, the hyperthyroid hyperthermic crisis of thyrotoxicosis may preferentially involve SKM over BAT. The tenet that UCP1 homologues are mediators of thyroid thermogenesis is also supported with the finding that UCP3 is significantly increased at the protein level by thyroid hormone in rodents.\textsuperscript{57-58} Together, the data support the argument that...
thermogenic mechanisms in SKM, involving the sarcoplasmic reticulum RYR1 and mitochondrial UCP3, are strong candidate mediators of muscle thermogenesis.

It should be mentioned that controversy exists dealing with UCP3 as a physiological thermogenic regulator. Soon after its identification in 1997, UCP3-null mice were generated and shown to protect body temperature normally as compared to wild type mice when exposed to cold. Soon after its identification in 1997, UCP3-null mice were generated and shown to protect body temperature normally as compared to wild type mice when exposed to cold.57 As made evident in numerous subsequent reviews, this singular observation led the UCP field to conclude that UCP3 may not, unlike UCP1, mediate NST at least in response to cold exposure. However, the mere lack of a cold-phenotype does not rule out the involvement of UCP3 in thermogenesis by different mechanisms, or the possibility that a thermogenic compensatory process has fulfilled the heat requirements in the UCP3-null background. As mentioned above, thyroid hormone is a potent inducer of SKM UCP3 protein along with its upstream regulator β3AR.46,56 In a study using a severely cold intolerant, β1,2,3AR adrenergic receptor-deficient “β-less” mouse model, T3 administration upregulated skeletal muscle UCP3, and drove oxygen consumption in muscle in the β-less background, but not in the β-less UCP3-null background.59 Although UCP3 is not an established regulator of BAT NST, these results provide evidence that it is a key thermogenic effector in SKM, at least in response to certain types of drug- or hormonally-regulated stimuli.

| Category                  | Component                        | Site       | Main Mediators                                                                 | Description of Thermogenic Systems                        |
|---------------------------|----------------------------------|------------|--------------------------------------------------------------------------------|-----------------------------------------------------------|
| Obligatory Thermogenesis  | Standard Metabolic Rate          | All Tissues| Thyroid Hormone, Leptin, Insulin, Glucagon                                    | Heat produced from all metabolic reactions necessary to maintain basic organ function |
| Facultative Thermogenesis | Shivering Thermogenesis          | SKM        | CNS                                                                            | Heat produced from muscle movement in response to cold    |
|                           | Non-Shivering Thermogenesis      | BAT        | SNS, Thyroid Hormone, Catecholamines                                           | Heat produced in response to cold and diet: UCP1 and UCP3(?) |
|                           |                                  | SKM        | SNS, Thyroid Hormone, Catecholamines, Serotoninergic Agents                    | Heat produced in response to cold and diet: UCP3 and Ca2+ cycling |
|                           | Movement-Related Heat Production | SKM        | CNS                                                                            | Heat produced from exercise (voluntary muscle movement). |
|                           | Malignant Hyperthermia           | SKM        | Genetic mutation in RYR1 in SKM Drug: Inhalational Anesthetic agents            | Heat produced from unregulated Ca2+ cycling when exposed to inhalation anesthetics |

Sympathomimetic-Induced Hyperthermia

Amphetamine-type drugs and their derivatives have long been associated with increased body heat production, hypermetabolism, catastrophic and lethal hyperthermia and skeletal muscle rhabdomyolysis. It is worth noting that amphetamine-type drugs and other sympathomimetics have different affinities for protein targets that affect the release and uptake of monoamines.61,62 For example, while cocaine and related analogs are selective, competitive inhibitors for dopamine monoamine transporters, MDMA acts as a competitive substrate for monoamine transporters and is relatively specific for serotonin.63 Therefore, these sympathomimetics have distinct neuropharmacological profiles that contribute to the central and peripheral effects of these agents, depending on their direct and indirect sympathomimetic actions. However, the final common pathway of SNS-hyperthermia through adrenergic mechanisms appears similar for sympathomimetics as a class.

3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) is a prototypical sympathomimetic amine agent and a worldwide major drug of abuse in large part because of its euphoric and stimulant properties.64 MDMA increases body heat production via multiple mechanisms of thermoregulation. Unsurprisingly, even though catastrophic hyperthermia is a relatively rare event in MDMA use, one of the most commonly reported subjective effects of MDMA in humans is a feeling of “being hot”.65 The idea that MDMA disrupts central regulation of body temperature is supported by observations that environmental ambient temperature and physical activity can profoundly affect the variability of MDMA-hyperthermic responses.66,67 In rodent models, hyperthermia occurs when MDMA is administered at ambient temperatures of 24°C or greater, and the degree of hyperthermia positively correlates with increasing ambient temperature.69,70 In contrast, low environmental temperatures can block the hyperthermic effects of MDMA,71 and even result in hypothermic responses.68 These observations
have important implications for MDMA users, where the drug is typically used in the setting of dance parties referred to as “raves” that increase the susceptibility to hyperthermia.

The challenge that arises from treating MDMA-induced hyperthermia stems from the complex and peripheral effects this agent can have on normal pathways of thermoregulation. MDMA administration is thought to cause a central deregulation of thermogenesis by altering the release of key monoamine neurotransmitters including serotonin, dopamine, and NE.72-75 and by affecting reuptake and transport of these neurotransmitters. Neuronal activation in response to neurotransmitter release of specific hypothalamic pathways in the supraoptic and median preoptic nuclei has been demonstrated with c-fos expression staining.76 MDMA and amphetamine derivatives have been shown to increase NE release,77 and also potentiate the effects of NE by blocking reuptake through the NE transporter.61,78-80 Furthermore, MDMA can act as substrate for the monoamine transporter that can be taken up into nerve terminals to cause the redistribution of cytoplasmic monoamine vesicles and lead to the reverse transport of neurotransmitters.63 These complex changes in neurotransmitter release and accumulation lead to alternations inadrenergic singaling that contribute to the peripheral effects of MDMA by affecting cutaneous vasonestriction of blood flow and stimulation of heat production in thermogenic effector organs SKM and BAT.62,81,82

**UCP3 and Thyroid Hormone in MDMA-Induced Hyperthermia**

Several lines of evidence support the hypothesis that SKM UCP3 is a major molecular mediator of sympathomimetic-induced hyperthermia. Foremost, the strongest evidence is that UCP3 knockout mice have severely blunted (80–100%) thermogenic responses to MDMA in vivo.45 Resistance to MDMA thermogenesis in UCP3 knockout mice also corresponds with complete protection from the lethal effects of the drug. Moreover, recent work showed that MDMA treatment in rodents led to a change in UCP3 protein phosphorylation and increased proton leak in the MDMA exposed animal SKM compared to controls.83 Consistent with the aforementioned study in β-less mice administered thyroid hormone, hyperthyroid and hypothyroid rats show dramatic increases or complete blunting, respectively, of MDMA hyperthermic responses, with body temperatures correlating in a near linear fashion with levels of UCP3 protein in isolated SKM mitochondria.84 Interestingly, a published case study showed that a woman that allegedly ingested 1–1.5 MDMA tablets (usually 150 mg MDMA) and died from hyperthermia had, on autopsy, subclinical hyperthyroidism.85 This suggests the likelihood that some of the idiosyncratic hyperthermic reactions to sympathomimetics could be thyroid hormone related.

The identification of UCP3 (and now also UCP1) as a thermogenic effector of sympathomimetic agents provides the opportunity to target these thermogenic proteins or their upstream mediators to mitigate in human cases of MDMA toxicity. After MDMA administration, the plasma levels of NE and sympathetic activity are elevated in human subjects.86 In rodents, NE increases by 35-fold in the bloodstream prior to the development of peak hyperthermia,25 as do levels of plasma free fatty acids.87 The absence of a concomitant rise in the NE metabolite dihydroxyphenylglycol following MDMA administration suggests that peripheral NE reuptake is also blocked.25 In response to increased plasma NE, triglyceride lipolysis leads to fatty acid release from white adipose tissue depots into the bloodstream. It is postulated that they serve as endocrine “thermokines” to activate UCP3 for SKM thermogenesis.87 Expression levels of α1- and β3-AR are relatively low in skeletal muscle.88-90 However, adrenergic actions may also be mediated directly in SKM, as made evident by observations from the Astrup lab that infusion of various adrenergic agonists and sympathomimetics can directly stimulate oxygen consumption in perfused muscle in rodents and humans.91,92 As depicted in Figure 1, the fatty acid activation model of SKM UCP3 contrasts with that of BAT, where the storage, lipolysis, liberation of fatty acid, and fatty acid activation of UCP1 each occurs within the brown adipocyte and its mitochondria.

Owing to the central role of the SNS, NE, and β3-AR, along with the α1-AR induced vasoconstriction in sympathomimetic hyperthermia, treatment of rodents with experimental adrenergic blocking drugs prevents MDMA hyperthermia in rodents, and dramatically decreases SKM rhabdomyolysis.25 Similarly, in clinically relevant work, treatment of rats with the pan αAR / βAR antagonist carvedilol completely blocks MDMA hyperthermia, and importantly, fully and rapidly resolves peak hyperthermia back to pre-treatment baseline temperatures.25 Importantly, carvedilol is the only FDA approved drug that antagonizes β3-AR. It is quite likely that this activity endows its treatment benefit in MDMA hyperthermia, because studies have shown in rodents that non-selective antagonists of β1-2-AR fail to block MDMA hyperthermia in the least.25 Results from the carvedilol study using rodents were recently repeated in MDMA-exposed humans, where the MDMA-induced rise in body temperature was fully blocked, but not the euphoric effects.93 As a bonus, carvedilol is generally regarded as a safe and well tolerated cardiovascular medicine and may be easy to employ in those cases when other supportive cooling measures and benzodiazepines fail to cool the hyperthermic patient. However, it is worth noting that the carvedilol is only available as an oral drug and exhibits variability in bioavailability due to poor gut perfusion. Furthermore, due to ethical considerations in the aforementioned clinical studies, subjects were given relatively low doses of MDMA and experienced only moderate hyperthermic responses. Therefore, additional studies are crucial in characterizing the drug’s clinical effectiveness in severe cases associated with MDMA toxicity.

**Uncoupling Proteins and Molecular Mechanisms in Other Thermogenic Conditions**

As mentioned above, many drug- and toxicant-induced hyperthermic conditions present with similar clinical symptoms when compared to sympathomimetic hyperthermia, and in most every
antidepressants, and MAOIs (Table 1). The tenet that the toxic thermogenic mechanisms associated with serotonin syndrome largely overlap with sympathomimetic syndrome is supported with experiments in animal models of serotonin syndrome showing enhanced levels of serotonin and norepinephrine in the anterior hypothalamus. It is likely that elevated serotonin levels increase central catecholamine release to alter hypothalamic regulation of the thyroid axis and peripheral release of NE. Unlike the hyperthermia observed with sympathomimetics, these central serotonin releasers are thought to have indirect effects on α1- and β3-adrenergic receptors, and that the potential uncoupling activity and heat generation in these conditions in BAT and SKM arises predominantly from NE release rather than a combined blockade of reuptake. Future work will be necessary to test the involvement of uncoupling proteins in response to non-sympathomimetic thermoregulation agents.

**UCP Hyperthermia Versus RYR1 “Malignant Hyperthermia”**

It has classically been assumed that MDMA hyperthermia must share a common mechanism with RYR1-mediated malignant hyperthermia, especially because the clinical and metabolic changes in both conditions are very similar. However, the literature indicates that the final heat-generating mechanisms of each syndrome are distinct, despite some potential upstream common regulatory features. As mentioned, MH is an autosomal dominant disorder caused by a mutation in RYR1, a major regulator of Ca2+ transport in SKM. It is triggered in susceptible patients by exposure to general anesthetic gases, and is clinically characterized by metabolic acidosis, hyperthermia, muscle rigidity, and rhabdomyolysis. The postulate that the mechanisms of MDMA-induced hyperthermia are analogous to MH is reasonable based on observations that both conditions produce SKM damage, and alterations in NE and serotonin signaling. However, unlike sympathomimetic hyperthermia, where activation of the SNS is the primary culprit behind massive heat generation, whether or not SNS and serotonergic modulation is causal or merely correlative in MH is not clear. Similar to what has been observed with MDMA toxicity in rodents, MH susceptible adrenalectomized pigs were also more resistant to MH toxicity, and treatment with thyroid hormone led to an earlier onset of MH in pigs, implicating activation of the hypothalamic-pituitary-adrenal and thyroid axes in MH. Despite the similarities, a recent study done by Schutte et al. to investigate whether MDMA could trigger MH in susceptible pigs found that there were no metabolic differences between MH-susceptible pigs and MH-normal pigs following MDMA exposure. This study, along with the finding that MDMA increases intracellular Ca2+ through a mechanism independent of the ryanodine receptor pathway in SKM, strongly suggests that MDMA is not a classic trigger of MH and works through a distinct biochemical mechanism to produce heat. This is also supported by studies using the RYR1 inhibitor dantrolene, the established and effective MH antagonist. Because of the erroneous assumption that...
MDMA hyperthermia and MH arise from the same mechanism, dantrolene has been indicated for treatment of MDMA hyperthermia. However, clinicians should be cognizant of the fact that the molecular mechanisms underlying these 2 pathologies are significantly divergent and should consider the possibility that other strategies may provide greater therapeutic benefit compared to dantrolene (i.e. adrenergic blockade) in extreme cases of MDMA hyperthermia.

Concluding Remarks

As shown in studies with MDMA and methamphetamine, it is likely that the family of uncoupling proteins, chiefly UCP1 and UCP3 play the dominant roles in the generation of the hyperthermic and SKM toxic responses to the vast majority of drugs that increase SNS activity via hypothalamic, serotonergic and direct peripheral adrenergic mechanisms. If true, this would predict that the use of the drug carvedilol may not only be useful for MDMA poisoning, but also in response to overdose with the cadre of sympathomimetics, and perhaps the newest members of this class – the bath salts. Testing the involvement of UCPs in a variety of thermogenic responses to other drugs and toxins will be of obvious importance.

It should also be noted that very interesting recent work highlights the fact that it would be erroneous to assume all sympathetetic activity is “the same” when considering thermogenesis and hyperthermia. Indeed, SNS activation by different stimuli can lead to diverse thermogenic responses. This was recently documented in a clinical report showing that cold exposure activated human BAT, but systemic treatment with a thermogenic dose of the sympathomimetic drug ephedrine failed to do so. This highlights the fact that much is to be learned regarding the neuro-anatomic distinctions that govern body temperature regulation to diverse SNS regulatory stimuli. Because so very few treatments exist, investigators will need to use strong mechanistic tools, tissue-targeted knockout mice, and neuro-tracing methodologies to provide a comparative assessment of the detailed mechanisms that distinguish the varied drug induced thermogenic syndromes. Recent clinical work identifying carvedilol as a potential sympathomimetic hyperthermia treatment is a step in the right direction.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

References

1. Stitt JT. Fever versus hyperthermia. Fed Proc 1979; 38:39-43; PMID:799237
2. Chan TC, Evans SD, Clark RF. Drug-induced hyperthermia. Crit Care Clin 1997; 13:785-808; PMID:9380481; http://dx.doi.org/10.1016/S0749-0704(05)70369-9
3. Muselman ME, Sady S. Diagnosis and treatment of drug-induced hyperthermia. Am J Health Syst Pharm 2013; 70:34-42; PMID:23261898; http://dx.doi.org/10.2146/app110543
4. Olson KR, Benowitz NL. Environmental and drug-induced hyperthermia. Pathophysiology, recognition, and management. Emerg Med Clin North Am 1984; 2:459-74; PMID:6534737
5. Rosenberg J, Pentel P, Pond S, Benowitz N, Olson K. Hyperthermia associated with drug intoxication. Crit Care Med 1986; 14:964-9; PMID:376909
6. Silva JE. Thermogenic mechanisms and their hormonal regulation. Physiol Rev 2006; 86:435-64; PMID:16601266; http://dx.doi.org/10.1152/physrev.00009.2005
7. Charkoudian N. Skin blood flow in adult human thermoregulation: how it works, when it does not, and why. Mayo Clin Proc 2003; 78:603-12; PMID:12744548
8. Nielsen B. Heat acclimation-mechanisms of adaptation to exercise in the heat. Int J Sports Med 1998; 19 Suppl 2:S154-6; PMID:9694425
9. De Witte J. Perioperative shivering: Physiology and pharmacology. Anesthesiology 2002; 96:467-484.
10. Morrison SF, Nakamura K. Central neural pathways for thermoregulation. Front Biosci (Landmark Ed) 2011; 16:74-104; PMID:21196101; http://dx.doi.org/10.2741/3677
11. Rusnack DE, Sprague JE. Toxic-induction of hyperthermic syndromes. Med Clin North America 2005; 89:1277-96; PMID:16226706; http://dx.doi.org/10.1016/j.mcnca.2005.06.002
12. Silva JE. Thermogenic mechanisms and their hormonal regulation. Physiol Rev 2006; 86:435-64; PMID:16601266; http://dx.doi.org/10.1152/physrev.00009.2005
13. Lin CS, Klingenberg M. Isolation of the uncoupling protein from brown adipose tissue mitochondria. FEBS Lett 1980; 113:299-303; PMID:7389900; http://dx.doi.org/10.1016/0014-5793(80)80613-2
14. Tjoaiev D, Lin C-S, Klingenberg M. Isolation of the GDP binding protein from brown adipose tissue mitochondria of several animals and amino acid composition study in rat. Biochim Biophys Acta Commun 190:586-9; PMID:6285923; http://dx.doi.org/10.1016/0006-291X(82)90115-0
15. Harper JA, Dickinson K, Brand MD. Mitochondrial uncoupling as a target for drug development for the treatment of obesity. Obes Rev 2001; 2:225-65; PMID:11219996; http://dx.doi.org/10.1046/j.1467-789X.2001.00043.x
16. Colman E. Dinitrophenol and obesity: an early twentieth-century regulatory dilemma. Regul Toxicol Pharmacol 2007; 48:115-7; PMID:17475379; http://dx.doi.org/10.1016/j.yrtph.2007.03.006
17. She P, Reid TM, Bronson SK, Vayr TC, Hajnal A, Lynch CJ, Hutton SM. Disruption of BAT in mice leads to increased energy expenditure associated with the activation of a futile protein turnover cycle. Cell Metabolism 2007; 6:181-94; PMID:17767995; http://dx.doi.org/10.1016/j.cmet.2007.08.003
18. Smith RE, Florwitz RA. Brown fat and thermogenesis. Physiol Rev 1969; 49:330-425; PMID:4888392
19. Nicholls DG, Locke RM. Thermogenic mechanisms in brown fat. Physiol Rev 1984; 64:1-64; PMID:2392232
20. Jezek P, Freidberg JE. Fatty acid binding site of the GDP binding protein from brown adipose tissue mitochondria of several animals and amino acid composition study in rat. Biochim Biophys Acta Commun 190:586-9; PMID:6285923; http://dx.doi.org/10.1016/0006-291X(82)90115-0
21. Cannon B, Nedergraad J. Brown adipose tissue function: tissue and physiological significance. Phys Rev Physiol 2004; 84:277-359; PMID:14715917; http://dx.doi.org/10.1152/physrev.00015.2003
22. Guerra C, Kosa RA, Walsh K, Kurts DM, Wood PA, Kozak LP. Abnormal nonsnghervin thermogenesis in mice with inherited defects of fatty acid oxidation. J Clin Invest 1998; 102:1724-31; PMID:9802886; http://dx.doi.org/10.1172/JCI34532
23. Zhao J, Cannon B, Nedergraad J. alpha1-Adrenergic stimulation potentiates the thermogenic action of beta3-adrenergoreceptor-generated cAMP in brown fat cells. J Biol Chem 1997; 272:32847-56; PMID:9407062; http://dx.doi.org/10.1074/jbc.272.52.32847
24. Fredriksen JM, Thonberg H, Oldson KB, Olba K, Cannon B, Nedergraad J. Analysis of inhibition by H89 of UCP1 gene expression and thermogenesis indicates protein kinase A mediation of beta(3)-adrenergic signalling rather than beta(3)-adrenergoreceptor antagonist by H89. Biochim Biophys Acta 2001; 1538:206-17; PMID:11336791
25. Sprague JE, Moze P, Caden D, Rusnack DE, Holmes C, Goldstein DS, Mills EM. Carvedilol reverses hyperthermia and attenuates rhodoblyolymphis induced by 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) in an animal model*. Crit Care Med 2005; 33:1311-6; PMID:15942349; http://dx.doi.org/10.1097/01.CCM.0000165969.29002.70
26. Nakrendorf M, Oldson KB, Fredriksen JM, Jacobsen A, Nedergraad J, Cannon B. Thermogenic responses in brown fat cells are fully UCP1-dependent. UCP2 or UCP3 do not substitute for UCP1 in adrenergically or fatty acid-induced thermogenesis. J Biol Chem 2006; 281:25973-81; PMID:16825155; http://dx.doi.org/10.1074/jbc.M000547200
27. Fedorenko A, Lishko PV, Kirchok Y. Mechanism of fatty-acid-dependent UCP1 uncoupling in brown fat mitochondria. Cell 151:400-13; PMID:23632128; http://dx.doi.org/10.1016/j.cell.2012.09.010
28. Sanchez-Alavez M, Sanchez-Alavez M1, Coni B, Wood MR, Bortell N, Bustamante E, Saez E, Fox HS, Marcondes MC, ROS and sympathetically mediated mitochondria activation in brown adipose tissue contribute to methaphetamine-induced hyperthermia. Front Endocrinol (Laval) 2013; 4:44; PMID:23630518
29. Cypess AM, Lehman S, Williams G, Tal I, Rodman D, Goldfine AB, Kuo PC, Palmer ES, Tseng YH, Doria A, et al. Identification and importance of brown adipose tissue in adult humans. N Engl J Med 2009; 360:1509-17; PMID:19537406; http://dx.doi.org/10.1056/NEJMoa0810780
30. Zingaretti MC, Crosta F, Vitali A, Guerrieri M, Fron- 
tini A, Cannon B, Nedergaard J, Cinti S. The pres- 
ence of UCPII demonstrates that metabolically active 
adipose tissue in the neck of adult humans truly repre- 
sents brown adipose tissue. FASEB J 2009; 23: 
3113-20; PMID:19417078; http://dx.doi.org/ 
10.1096/fj.09-133546

31. Soderlund V, Larsson SA, Jacobsson H. Reduction of 
FDG uptake in brown adipose tissue in clinical 
patients with a history of propranolol. Eur J Nucl 
Med Mol Imaging 2007; 34:1018-22; PMID:17225118; 
http://dx.doi.org/10.1007/s00259- 
006-0318-9

32. Christensen CR, Clark PB, Morton KA. Reversal of 
reversal to malignant hyperthermia. Nature 1990; 
343:559-61; PMID:2195897; http://dx.doi.org/10. 
1038/343559a0

33. Enerback S. Human brown adipose tissue. Cell Metab 
2006; 5:17-26; PMID:16692385; http://dx.doi. 
org/10.1016/j.cmet.2006.01.007

34. Heaton JM. The distribution of brown adipose tissue 
in the human. J Anat 1972; 112:35-9; 
PMID:5146828

35. Harri M, Hedenstam R. Calorigenic effect of adrena-
line and noradrenaline in the frog, Rana temporaria. 
Comp Biochem Physiol A Comp Physiol 1972; 
49:235-9; PMID:4575923; http://dx.doi.org/10. 
1016/0300-9629(72)90071-0

36. Vidal-Puig AJ, Salazar G, Grigic D, Fler J, Lowell BB. 
UCPII: an uncoupling protein homologue expressed 
preferrentially and abundantly in skeletal muscle and 
brown adipose tissue. Biochem Biophys Res Comm 
1997; 235:79-82; PMID:9160599; 
http://dx.doi.org/10.1016/S0006- 
2977(97)99779-1

37. Lago C, Nowinski SM, Rundhaug JE, Pfeiffer MF, 
Kiigachi K, Hirakasa K, Yang X, Abramson EM, Bot-
ton SB, Rho O, et al. Mitochondrial respiratory uncoupling 
improves keratinocyte differentiation and blocks 
skin carcinogenesis 2012; 31:4725-31; 
PMID:22266853

38. Jaburek M, Varecha M, Gimeno RE, Dembski M, 
Jezek P, Zhang M, Burn P, Tartaglia LA, Garlid KD. 
Transport function and regulation of mitochondrial 
un coupling proteins 2 and 3. J Biol Chem 1999; 
274:26603-7; PMID:10473545; 
http://dx.doi.org/10.1074/jbc.274.37.26603

39. Boss O, Hagen T, Lowell BB. Uncoupling proteins 2 
and 3: potential regulators of mitochondrial energy 
metabolism. Diabetes 2000; 49:143-5; 
PMID:10868929; http://dx.doi.org/10.2337/diabetes. 
49.2.143

40. Hardinge MG, Peterson DI. The effects of exercise 
and limitation of movement on amphetamine toxic-
ity. J Pharmacol Exp Ther 1963; 141:260-5; 
PMID:1404081

41. Bal NC, Maurya SK, Sopariwala DH, Sahoo SK, 
and energy balance. Thyroid 1995; 5:481-92; 
PMID:10.1038/426403a

42. Means of noradrenalin action during non-shivering 
thermogenesis in a novel muscle cell modified for 
heat production. J Cell Biol 1988; 109:1079-112; 
PMID:3417775; http://dx.doi.org/10.1083/j. 
1034.109

43. Bal NC, Maurya SK, Sopariwala DH, Sahoo SK, 
and energy balance. Thyroid 1995; 5:481-92; 
PMID:10.1038/426403a

44. Waldman E. Acute and long-term effects of 3,4-
methylenedioxymethamphetamine (MDMA) and related 
aromatic amphetamine derivatives on inhibition of 
uptake of [3H]monoamines into synap-
somes from different brain regions. Biochem 
Pharmacol 1987; 36:2297-30; PMID:2886126; 
http://dx.doi.org/10.1016/0006- 
2957(87)90594-6

45. Docherty JR, Green AR. The role of monoamines in 
the changes in body temperature induced by 3,4-
methylenedioxymethamphetamine (MDMA, ecstasy) 
and its derivatives. Br J Pharmacol 2010; 160: 
1029-44; PMID:2059097; 
http://dx.doi.org/10.1111/j.1476-531X.2010.00722.x

46. Torre GE, Gainetdinov RR, Caron MC. Plasma 
metabolites of monoamine transporters: structure, regula-
tion and function. Nat Rev Neurosci 2003; 4:13-25; 
PMID:12511988; http://dx.doi.org/10.1038/nrn1008

47. Green AR, Mechan AO, Elliott JM, O’Shea E, 
Colado MI. The pharmacology and clinical pharma-
ology of 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’). Pharmacol Rev 2003; 55: 
463-508; PMID:12869661; 
http://dx.doi.org/10.1124/pr.55.3.3

48. Parrott AG, Lock J, Conner AC, Kieling C, Thome J. 
Dance clubbing on MDMA and during abstinence 
from Ecstacy(MDMA): prospective neuroendocrine 
and psychological changes. Neuropsychobiology 
2008; 57:165-80; PMID:18654086; 
http://dx.doi.org/10.1159/ 
00019198

49. Stephenson CP, Hunt GE, Topple AN, McGregor IS. 
The distribution of 3,4-methylenedioxymethamphetamine 
‘Ecstasy’-induced c-fos expression in rat brain.

81. Blessing WW, Zilm A, Ootsuka Y. Clozapine reverses human system involvement in hyperthermia induced by the thalamic-pituitary-thyroid axis and sympathetic nervous system. J Clin Pharm Ther 2000; 25:549-57; PMID:10941349; http://dx.doi.org/10.1016/S0300-1971(00)00053-9

99. Mason PJ, Morris V, Balcezak T. Serotonin syndrome. Ann Clin Psychiat 2012; 24:310-3; PMID:22484344; http://dx.doi.org/10.1177/0268900212434434

89. Sillence MN, Moore NG, Pegg GG, Lindsay DB. Spinal muscle membrane pumps. Br J Pharmacol 1993; 109:1157-63; PMID:8144645; http://dx.doi.org/10.1111/j.1476-5381.1993.tb13743.x

97. McCaig DJ, Docherty JR. Vascular actions of MDMA involve alpha1 and alpha2-adrenoceptors in the anaesthesized rat. Br J Pharmacol 2001; 133:429-37; PMID:11375260; http://dx.doi.org/10.1038/bjp.0704949

87. Leonardi ET, Azmitia EC. MDMA (ecstasy) inhibits release of MAO type A and type B. Comparisons with fenfluramine and fluoxetine (Prozac). Neuropsychopharmacology 1994; 10:231-8; PMID:7945733; http://dx.doi.org/10.1038/1994.26

86. Stuerenburg HJ, Petersen K, B aumer T, Rosenkranz M, Moore BM. The preservation of in vivo cardiovascular functions in isolated cardiovascular tissues. J Pharm Pharmacol 2003; 55:1731-4; PMID:12969746; http://dx.doi.org/10.1016/S0022-3578(03)02173-3

85. Fitzgerald JL, Reid JJ. Sympathomimetic actions of methylenedioxymethamphetamine in rat and rabbit isolated carotid sinus vessels. J Pharm Pharmacol 1994; 46:826-32; PMID:7699571; http://dx.doi.org/10.1111/j.1040-6381.1994.tb01738.x

84. Blessing WW, Zilm A, Ootsuka Y. Clozapine reverses increased brown adipose tissue thermogenesis induced by 3,4-methylenedioxymethamphetamine and by cold exposure in conscious rabbits. Neuroscience 2006; 141:2067-73; PMID:16814930; http://dx.doi.org/10.1016/j.neuroscience.2006.05.050

83. Blessing WW, Zilm A, Ootsuka Y. Clozapine reverses increased brown adipose tissue thermogenesis induced by 3,4-methylenedioxymethamphetamine and by cold exposure in conscious rabbits. Neuroscience 2006; 141:2067-73; PMID:16814930; http://dx.doi.org/10.1016/j.neuroscience.2006.05.050

82. Pedone C, Maggini S, Fantoni MU. Cutaneous vasconstriction contributes to hyperthermia induced by 3,4-methylenedioxymethamphetamine (ecstasy) in conscious rabbits. J Neurosci 2001; 21:8648-54; PMID:11417624; http://dx.doi.org/10.1016/S0022-2836(01)00482-6

81. Blessing WW, Zilm A, Ootsuka Y. Clozapine reverses increased brown adipose tissue thermogenesis induced by 3,4-methylenedioxymethamphetamine and by cold exposure in conscious rabbits. Neuroscience 2006; 141:2067-73; PMID:16814930; http://dx.doi.org/10.1016/j.neuroscience.2006.05.050

80. Sillence MN, Moore NG, Pegg GG, Lindsay DB. Spinal muscle membrane pumps. Br J Pharmacol 1993; 109:1157-63; PMID:8144645; http://dx.doi.org/10.1111/j.1476-5381.1993.tb13743.x

79. Cleary L, Docherty JR. Actions of amphetamine derivatives and cathine on the noradrenaline transport. Eur J Pharmacol 2003; 476:31-4; PMID:12969746; http://dx.doi.org/10.1016/S0014-2999(03)02173-3

78. Leonardi ET, Azmitia EC. MDMA (ecstasy) inhibits release of MAO type A and type B. Comparisons with fenfluramine and fluoxetine (Prozac). Neuropsychopharmacology 1994; 10:231-8; PMID:7945733; http://dx.doi.org/10.1038/1994.26

77. McCaig DJ, Docherty JR. Vascular actions of MDMA involve alpha1 and alpha2-adrenoceptors in the anaesthesized rat. Br J Pharmacol 2001; 133:429-37; PMID:11375260; http://dx.doi.org/10.1038/bjp.0704949